Concerns regarding counterfeit medications were voiced in Parliament recently as Fiji’s Health Minister, Dr. Ratu Atonio Lalabalavu, presented information about Fiji’s new Pharmacopeia Agreement with India. During the discussion, Opposition MP Joseph Nand described the agreement as a “significant milestone” aimed at ensuring timely access to high-quality pharmaceuticals.
India, recognized as the “pharmacy of the world,” supplies pharmaceuticals to over 200 countries. The memorandum of understanding (MOU) is expected to provide Fiji with enhanced access to medicines at lower costs. Yet, MP Premila Kumar raised concerns regarding safeguards against counterfeit drugs, asking, “What provisions or what mechanisms are in place to ensure counterfeit drugs or fake medicine do not come into the country?”
In response, Dr. Lalabalavu assured that both India and Fiji have established checks, emphasizing that local tests would still be performed on all drugs imported under this agreement. He reflected on visits to Indian facilities that manufacture these medications, indicating a commitment to uphold quality standards.
The MOU comes at a critical time, as Fiji’s health system has faced enduring challenges related to medication shortages exacerbated by global supply chain disruptions. Earlier initiatives, including direct procurement arrangements with Indian manufacturers, demonstrate the government’s proactive approach to addressing these shortages.
To strengthen the healthcare framework, the government aims to integrate the international standards set by the Indian Pharmacopoeia Commission into its regulatory practices, ensuring a consistent quality for medications. Previous commitments outlined by Prime Minister Sitiveni Rabuka, including an agreement to promote greater access to essential medications, align with these efforts.
As Fiji reinforces its ties with India and implements critical health initiatives, there is optimism that these collaborative actions will lead to improved healthcare outcomes, paving the way for a more resilient health system capable of responding to future challenges. This commitment ensures that all Fijians have reliable access to necessary pharmacological treatments while safeguarding against counterfeit and ineffective medications, thus enhancing overall public health safety.